Ann: PBT434 at the 6th International Multiple System Atrophy Conf, page-5

Prana told last week: "

Prana is continuing to evaluate this candidate in mouse models of atypical Parkinsonism, including synucleinopathies (e.g., Multiple System Atrophy) and tauopathies (e.g., Progressive Supranuclear Palsy)". ​

So they have not published anything on Progressive Supranuclear Palsy. But it may come before the Phase1 is done. ​

It is a bit more common than MSA, but still an orphan disease. Let us see if they will target both of these diseases before PD phase 3 study. But I would say that a MSA phase 2 study will be started after the phase 1. One orphan indication is enough.